Pharmaceuticals Analyst Schott and Biotech Analysts Fye, Cheng & Rama, along with Key Opinion Leaders Dr. Hatim Husain of UCSD and Dr. Joshua Sabari of NYU College of Medicine, discuss their perspectives on the lung cancer landscape (relevant companies MRK, AZN, GILD, SGEN, NVCR, NUVL, BCAB) on an Analyst/Industry conference call to be held on March 16 at 10 am. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck downgraded at Wells Fargo on valuation, lack of catalysts
- Merck downgraded to Equal Weight from Overweight at Wells Fargo
- Merck says Phase 2/3 CCTG IND.227/KEYNOTE-483 trial met primary endpoint
- Merck price target raised to $130 from $125 at Berenberg
- Merck price target raised to $123 from $116 at Guggenheim
